{"product_id":"csl-bcg-matrix","title":"CSL Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThe CSL BCG Matrix snapshot shows which product lines are pulling their weight and which need a new play — a quick read on Stars, Cash Cows, Question Marks, and Dogs within CSL’s portfolio. Want the full picture? Purchase the complete BCG Matrix for quadrant-by-quadrant placements, data-backed recommendations, and a ready-to-use Word and Excel pack. Skip the guesswork and get strategic clarity now — act where it counts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCSL Seqirus influenza vaccines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMassive demand cycles and pandemic readiness keep CSL Seqirus on a steep growth curve, supported by the fact seasonal influenza causes an estimated 290,000–650,000 respiratory deaths annually (WHO). Market share is strong across key markets with trusted government and health-system relationships. Continue investing in capacity, next‑gen platforms and distribution to lock in the lead; as uptake stabilizes this can glide into Cash Cow territory.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlasma-derived immunoglobulins (PID, CIDP)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical need for plasma-derived immunoglobulins is expanding with global IG demand \u0026gt;US$12bn in 2023 and mid-single-digit CAGR as diagnosis rates and access widen; CSL’s scale — operating ~270 plasma collection centres — and integrated fractionation deliver high share and reliable availability (CSL Behring among top global suppliers). It remains cash-intensive for collection, fractionation and network expansion, but defending share now positions CSL to harvest higher returns as demand grows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty plasma for rare bleeding disorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh medical urgency and strong clinician trust drive brisk uptake in growth markets for specialty plasma in rare bleeding disorders; hemophilia A affects about 1 in 5,000 male births and hemophilia B about 1 in 25,000, keeping demand steady. CSL’s deep portfolio and relationships with centers of excellence keep it top‑of‑mind. Ongoing medical education and market access muscle are required; sustained execution can compound into durable leadership.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecombinant hemophilia therapies (selected assets)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn 2024 switch dynamics and longer‑acting profiles continued to drive recombinant hemophilia category growth; where CSL holds strong positions, share gains plus positive clinical data are sustaining momentum. Competitive heat remains high, keeping promo and access spend elevated, so CSL must keep backing winners to outpace class averages.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 trend: EHL-driven switch fueling market expansion\u003c\/li\u003e\n\u003cli\u003eCSL advantage: share gains supported by clinical readouts\u003c\/li\u003e\n\u003cli\u003eCost: sustained promo\/access investment due to competition\u003c\/li\u003e\n\u003cli\u003ePriority: double down on top assets to beat class growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCSL Vifor iron therapies in expanding markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCSL Vifor iron therapies sit in Stars as CKD and iron‑deficiency care pathways scale: ~850 million people have CKD and ~1.8 billion suffer iron deficiency (WHO\/GBD 2023), driving rising hospital and outpatient adoption in 2023–24. Continued market education and tender wins are required; push now while the category is breaking out.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh prevalence: CKD ~850M; ID ~1.8B\u003c\/li\u003e\n\u003cli\u003eAdoption: hospital + outpatient growth 2023–24\u003c\/li\u003e\n\u003cli\u003eNeeds: education, tender wins\u003c\/li\u003e\n\u003cli\u003ePriority: accelerate market capture\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharma readies for flu, plasma, hemophilia \u0026amp; CKD\/ID growth — scale, R\u0026amp;D, access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCSL Stars: Seqirus rides influenza demand (290,000–650,000 deaths\/yr WHO) and pandemic readiness; Behring leads plasma (global IG \u0026gt;US$12bn 2023; ~270 plasma centres); recombinant hemophilia growth sustained by 2024 EHL switches; Vifor scales in CKD\/ID (CKD ~850M; ID ~1.8B). Priorities: capacity, next‑gen R\u0026amp;D, market access and focused promo to convert growth into cash flow.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2023–24 metric\u003c\/th\u003e\n\u003cth\u003eCSL position\u003c\/th\u003e\n\u003cth\u003ePriority\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSeqirus\u003c\/td\u003e\n\u003ctd\u003eInfluenza burden 290k–650k\u003c\/td\u003e\n\u003ctd\u003eStrong gov't share\u003c\/td\u003e\n\u003ctd\u003eCapacity\/capex\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBehring\u003c\/td\u003e\n\u003ctd\u003eIG \u0026gt;US$12bn\u003c\/td\u003e\n\u003ctd\u003eTop supplier; ~270 centres\u003c\/td\u003e\n\u003ctd\u003eCollection scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHemophilia\u003c\/td\u003e\n\u003ctd\u003eEHL switch 2024\u003c\/td\u003e\n\u003ctd\u003eShare gains\u003c\/td\u003e\n\u003ctd\u003eBack winners\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVifor\u003c\/td\u003e\n\u003ctd\u003eCKD 850M; ID 1.8B\u003c\/td\u003e\n\u003ctd\u003eGrowing adoption\u003c\/td\u003e\n\u003ctd\u003eEducation\/tenders\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review of CSL's units, with clear quadrant insights and recommendations to invest, hold or divest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page CSL BCG Matrix aligning portfolio pain points to strategy — ready to print, present, or drop into slides.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlbumin for hospital and critical care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMature hospital\/critical-care albumin has steady, sticky institutional contracts delivering predictable cash flow and low incremental promotion needs; scale drives cost efficiency across plasma sourcing and fractionation, keeping per-unit COGS low. Prioritize manufacturing throughput and regional logistics optimization to preserve high margins and free cash for portfolio reinvestment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy immunoglobulin indications in mature markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEstablished prescriber habits and reimbursement in mature markets keep CSL's legacy immunoglobulin volumes broadly stable, supporting steady annual cash flow; the global IVIG market was roughly USD 18.5 billion in 2024. Brand trust and supply reliability favor CSL, underpinning premium uptake and low churn. Growth is minimal (low-single-digit), but cash conversion remains excellent. Maintain service levels and avoid price leaks to preserve margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSeasonal flu vaccines in stable geographies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSeasonal flu vaccines in stable geographies provide forecastable demand via annual procurement cycles and repeat tenders, with global production roughly 500–900 million doses per year. Efficient fill‑finish runs and harvested manufacturing learning curves keep unit costs low, making the franchise cash positive despite routine lifecycle management. Milk revenues while reallocating R\u0026amp;D into next‑gen platforms; Seqirus is among the top three global suppliers. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished nephrology supportive therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEstablished nephrology supportive therapies are embedded in dialysis protocols with predictable utilization and stable demand; the US dialysis population remains ~550,000 patients (2024), anchoring recurring volume. Competitive set is well known and switching is low, enabling solid margins with modest upkeep; keep contracts tight and operations lean to protect cash flow.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEmbedded protocols: predictable utilization\u003c\/li\u003e\n\u003cli\u003eMarket: US dialysis ~550,000 patients (2024)\u003c\/li\u003e\n\u003cli\u003eSwitching: low, known competitors\u003c\/li\u003e\n\u003cli\u003eEconomics: solid margins, modest upkeep\u003c\/li\u003e\n\u003cli\u003ePlaybook: tight contracts, lean operations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContracted government supply agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eContracted government supply agreements act as cash cows for CSL by smoothing volume and capacity planning through long-term buys; CSL reported FY2024 revenue of about A$13.0 billion, with government programs providing a durable, low-volatility cash base. Once agreements are secured, incremental sales costs are limited and cash visibility is high, supporting predictable free cash flow. Maintaining reliability SLAs above contractual targets preserves renewal rates and pricing leverage.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLong-term buys: smoothes production planning\u003c\/li\u003e\n\u003cli\u003eLow incremental sales cost: improves margins\u003c\/li\u003e\n\u003cli\u003eHigh cash visibility: reduces volatility\u003c\/li\u003e\n\u003cli\u003eSLAs critical: drives renewals and pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSteady cash: high-margin albumin, IVIG, flu vaccines and nephrology fuel A$13.0bn FY2024\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMature albumin, legacy IVIG and Seqirus flu vaccines plus nephrology therapies and long‑term government contracts generate predictable, high‑margin cash for CSL; FY2024 revenue ~A$13.0bn. IVIG market ~USD18.5bn (2024); US dialysis ~550,000 patients (2024); flu supply 500–900M doses\/yr. Prioritize throughput, contract retention and tight SLAs to sustain free cash.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash Cow\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlbumin\u003c\/td\u003e\n\u003ctd\u003eStable institutional contracts\u003c\/td\u003e\n\u003ctd\u003eHigh margin, low promo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIVIG\u003c\/td\u003e\n\u003ctd\u003eGlobal market USD18.5bn\u003c\/td\u003e\n\u003ctd\u003eSteady cash flow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSeqirus\u003c\/td\u003e\n\u003ctd\u003e500–900M doses\/yr\u003c\/td\u003e\n\u003ctd\u003eRepeat annual revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNephrology\u003c\/td\u003e\n\u003ctd\u003eUS dialysis ~550k\u003c\/td\u003e\n\u003ctd\u003eRecurring demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovt contracts\u003c\/td\u003e\n\u003ctd\u003eContributes to A$13.0bn\u003c\/td\u003e\n\u003ctd\u003eVolume visibility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eCSL BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact CSL BCG Matrix report you'll receive after purchase. No watermarks, no demo text—just the fully formatted, market-tested analysis ready for strategy meetings. After buying, the final document is delivered immediately for editing, printing, or sharing with stakeholders. It's designed for clarity and action, so there are no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56163353493881,"sku":"csl-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/csl-bcg-matrix.png?v=1762718135","url":"https:\/\/portersfiveforce.com\/products\/csl-bcg-matrix","provider":"Porter's Five Forces","version":"1.0","type":"link"}